Table 1 Tumour characteristics and adjuvant treatment of patients with HER-2-positive breast cancer
Characteristic | Patients without chemotherapy or trastuzumab ( n =89) | All HER-2-positive patients ( n =168) |
|---|---|---|
Age | ||
Median (range) | 50 (28–79) | 49 (28–79) |
Tumour size | ||
T1 | 46 (52%) | 89 (53%) |
T2/3 | 43 (48%) | 79 (47%) |
Lymph node status | ||
N0 | 55 (62%) | 96 (57%) |
N1 | 34 (38%) | 73 (43%) |
Histological grade | ||
Grade 1/2 | 35 (39%) | 64 (38%) |
Grade 3 | 53 (60%) | 104 (62%) |
ER status | ||
Positive | 57 (64%) | 103 (61%) |
Negative | 32 (36%) | 64 (38%) |
PR status | ||
Positive | 36 (40%) | 70 (42%) |
Negative | 53 (60%) | 98 (58%) |
Adjuvant treatment | ||
Untreated | 53 (60%) | 53 (32%) |
Hormonal therapy | 36 (40%) | 66 (39%) |
Chemotherapy | 0 | 77 (46%) |
Trastuzumab | 0 | 25 (15%) |
